1. Home
  2. NBTB vs AGIO Comparison

NBTB vs AGIO Comparison

Compare NBTB & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NBT Bancorp Inc.

NBTB

NBT Bancorp Inc.

HOLD

Current Price

$50.28

Market Cap

2.6B

Sector

Finance

ML Signal

HOLD

Logo Agios Pharmaceuticals Inc.

AGIO

Agios Pharmaceuticals Inc.

HOLD

Current Price

$41.23

Market Cap

2.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NBTB
AGIO
Founded
1856
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.6B
2.2B
IPO Year
1995
2013

Fundamental Metrics

Financial Performance
Metric
NBTB
AGIO
Price
$50.28
$41.23
Analyst Decision
Strong Buy
Buy
Analyst Count
3
8
Target Price
$51.33
$38.88
AVG Volume (30 Days)
368.9K
1.3M
Earning Date
04-23-2026
04-29-2026
Dividend Yield
3.39%
N/A
EPS Growth
12.12
N/A
EPS
0.98
N/A
Revenue
$182,952,000.00
$43,011,000.00
Revenue This Year
$16.82
$76.75
Revenue Next Year
$4.88
$170.73
P/E Ratio
$50.97
N/A
Revenue Growth
10.40
N/A
52 Week Low
$39.21
$22.24
52 Week High
$51.09
$46.00

Technical Indicators

Market Signals
Indicator
NBTB
AGIO
Relative Strength Index (RSI) 64.46 69.84
Support Level $41.60 $39.31
Resistance Level $51.09 $43.72
Average True Range (ATR) 1.08 1.73
MACD 0.02 0.52
Stochastic Oscillator 81.84 71.91

Price Performance

Historical Comparison
NBTB
AGIO

About NBTB NBT Bancorp Inc.

NBT Bancorp Inc is a financial holding company that operates through its subsidiaries. The company's principal sources of revenue include management fees and dividends it receives through its subsidiaries. Its business, predominantly conducted through NBT Bank, consists of providing commercial banking, retail banking, and wealth management services to customers in its market area, which includes upstate New York, northeastern Pennsylvania, southern New Hampshire, western Massachusetts, Vermont, southern Maine, and central and northwestern Connecticut. The company's reportable segments are Banking and Retirement Plan Administration. A majority of its revenue is generated from the Banking segment.

About AGIO Agios Pharmaceuticals Inc.

Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.

Share on Social Networks: